← Back to Search

Other

D-4517.2 for Age-Related Macular Degeneration (Tejas Trial)

Phase 2
Recruiting
Research Sponsored by Ashvattha Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 21 days
Treatment 24 weeks
Follow Up 1 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new injectable drug, D-4517.2, in people with wet AMD or DME. The drug aims to block a protein that causes harmful blood vessel growth in the eye, potentially preventing further vision loss.

Eligible Conditions
  • Age-Related Macular Degeneration
  • Diabetic Macular Edema

Timeline

Screening ~ 21 days
Treatment ~ 24 weeks
Follow Up ~1 weeks
This trial's timeline: 21 days for screening, 24 weeks for treatment, and 1 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants with Treatment-Emergent Adverse Events [Safety]
Secondary study objectives
Number of participants with Ocular and non-ocular adverse events (AEs) and serious adverse events (SAEs) observed for D-4517.2 and aflibercept
Number of participants with a reduction in sub-retinal fluid after a single intravitreal (IVT) dose of aflibercept and a single SC dose of D-4517.2
Number of participants with change in best corrected visual acuity (BCVA) in study eye after each treatment (aflibercept or D-4517.2).
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Neovascular Age-related Macular DegenerationExperimental Treatment1 Intervention
Cohort A1 - 0.25 mg/kg of D-4517.2 Cohort B1 - 0.5 mg/kg of D-4517.2 Cohort C1 - 1.0 mg/kg of D-4517.2 Cohort D1 - 2.0 mg/kg of D-4517.2
Group II: Diabetic Macular EdemaExperimental Treatment1 Intervention
Cohort B2 - 0.5 mg/kg of D-4517.2 Cohort C2 - 1.0 mg/kg of D-4517.2 Cohort D2 - 2.0 mg/kg of D-4517.2
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
D-4517.2
2022
Completed Phase 1
~20

Find a Location

Logistics

Other reimbursement is provided

Other forms of reimbursement are provided for this trial.

Who is running the clinical trial?

Ashvattha Therapeutics, Inc.Lead Sponsor
3 Previous Clinical Trials
109 Total Patients Enrolled
~9 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top